Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Case of Complete Response to Immunotherapy in MMR-Deficient Prostate Cancer Associated with NK-like and CD4+CD8+ T-cells

ABSTRACT: Mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) are rare in prostate cancer, occurring in 2-4% of cases. These defects result in increased genomic instability and elevated tumor mutational burden (TMB), which can support responses to immune checkpoint inhibitors (ICIs). Here, we report a patient with locally-advanced Gleason 5+5=10 prostatic adenocarcinoma harboring MSH2 and MSH6 genomic deletions with ultrahigh TMB (>250 mutations/megabase) in whom pembrolizumab resulted in a striking complete radiographic, pathologic, and molecular response. Using digital-spatial microscopy, single-cell RNA/TCR-sequencing, and multiplex cytometry, we identify atypical tumor-infiltrating T-cells with natural killer-like phenotypes and CD4+CD8+ (double-positive) lymphocytes. These unique and clonal T-cell populations expand preferentially following ICI and adopt terminally-differentiated and cytotoxic profiles that may drive clinical response. Similar T-cells are also present in diverse cancers and expand exclusively in ICI-responsive patients. These findings inform on cellular mechanisms by which immunotherapies may mediate profound responses in patients with dMMR solid tumors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE332846 | GEO | 2026/05/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment of glioblastoma

Project description:Mutations in DNA mismatch repair (MMR) pathway genes (MSH2, MSH6, MLH1, and PMS2) have been associated with acquired resistance to temozolomide and with a high tumor mutation burden (TMB) in high-grade gliomas (HGG), including glioblastoma (GBM). However, the specific roles of individual MMR genes in the initiation, progression, increased TMB and microsatellite instability (MSI), and resistance to temozolomide (TMZ) in glioma have not been extensively studied. In the present study, we developed de novo mouse models of germline and somatic MMR-deficient (MMRd) HGG. Surprisingly, we found that loss of Msh2 or Msh6 does not lead to a high TMB and MSI nor confer response to anti-PD-1 in GBM. Our data also revealed that germline MMRd leads to the transition from low to high-grade glioma. Additionally, we show that mice with germline MMRd had reduced survival compared to MMR-proficient (MMRp) tumor-bearing mice. This effect was tumor cell intrinsic but was associated with MMRd in the tumor immune microenvironment, which led to increased immunosuppressive pathways in myeloid cells, reduced lymphoid infiltration, and increased exhaustion of CD8+ T cells. We have found that both MMR-reduced (MMRr) and MMRd GBM are resistant to TMZ, unlike MMRp tumors. Our study shows that KL-50, a new imidazotetrazine-based DNA targeting agent designed to induce DNA interstrand cross-links, is effective in treating both germline and somatic MMRr and MMRd GBM-bearing mice. These findings present a new treatment option for HGG patients with inherited or acquired MMRd who are resistant to TMZ.

2025-12-15 | GSE292092 | GEO

RNA-seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancer With and Without Defective DNA Mismatch Repair

Project description:Tumor mutation burden (TMB) is an evolving biomarker for predicting response to immune checkpoint inhibitors (ICI’s). The goal of this study was to evaluate the use of RNA-seq for determining TMB in patients with defective DNA MMR (dMMR) due to MMR mutations or MLH1 promoter hypermethylation (HM) and tumors without dMMR. We included tumors and paired normal tissue from 58 patients for TMB analysis using RNA-seq. Forty-six tumors were MSI-H (29 with a DNA MMR germline mutation and 17 with MLH1 promoter HM) and 12 were MSS. TMB was measured using the expressed somatic nucleotide variants (eTMB). We developed a method that leverages mutational signatures to remove FFPE derived artifact from total eTMB and thereby accurately measure the eTMB. There was a significant difference in the eTMB observed between MSI-H and MSS cases; MSI-H cases had a median of 27.3 mutations/Mb compared to 6.7 mutations/Mb for MSS cases (p=3.5e-9). Among tumors with dMMR the tumors with DNA MMR mutations had a significantly higher eTMB (p=0.037) than tumors with MLH1 promoter HM: a median of 28.1 mutations/Mb vs. a median of 17.5 mutations/Mb. Furthermore, through multivariate analysis we found that MSI status, tissue type (endometrial or colorectal) and patient ages are significantly associated with eTMB. These results demonstrate that RNA-seq analysis can be used to measure eTMB in FFPE tumor specimens. Further studies are needed to determine how eTMB as determined by RNA-seq compares to TMB as determined by DNA-based NGS assays

2020-03-13 | GSE146889 | GEO

Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer

Project description:In patients diagnosed as endometrial cancer by thorough pathologic examinations, Lynch syndromes are screened by (1)immunohistochemical staining (for MLH1, MSH2, MSH6 and PMS2), (2) tests of microsatellite instability and (3) clinical criteria (Amsterdam I or II criteria and Bethesda criteria). For patients with any suspicious discoveries of Lynch syndromes from aforementioned screening methods, a molecular diagnosis with next-generation sequencing for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) is given to confirm Lynch syndromes. For patients of Lynch syndromes and endometrial cancer, relatives of blood lineage are tested by Sanger method or qPCR to find out carriers of mutation genes of Lynch syndromes.

| 2254970 | ecrin-mdr-crc

Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.

Project description:Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair- deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high microsatellite instability (MSI), they had markedly distinct immune phenotypes. The first displayed a dense infiltrate of lymphocytes (“hot nodule”), while the second displayed significantly fewer infiltrating lymphocytes (“cold nodule”). Whole-exome DNA analysis found that both nodules shared many identical mutations, indicating that they were derived from a single clone. However, the cold nodule appeared to be sub-clonal relative to the hot nodule, suggesting divergent evolution of the cold nodule from the hot nodule. Whole-transcriptome RNA analysis found that the cold nodule demonstrated lower expression of genes related to antigen presentation (HLA) and, paradoxically, classical tumor immune tolerance markers such as PD-L1 (CD274) and CTLA-4. Immune cell deconvolution suggested that the hot nodule was enriched not only in CD8+ and CD4+ T lymphocytes, but also in M1 macrophages, activated NK cells, and gamma delta T cells compared to the cold nodule. This case highlights that MMRd/TMB-high PC can evolve to minimize an anti-tumor immune response, and nominates downregulation of antigen presentation machinery (HLA loss) as a potential mechanism of adaptive immune evasion in PC.

2023-10-31 | GSE246684 | GEO

proliferation CRISPR screen from WTC11 (ENCSR900AXT)

Project description:Cell survival-based CRISPR screen targeting genomic regions near MSH2, MSH6, MLH1, PMS2, PCNA and HPRT1 genes. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2026-02-28 | GSE321467 | GEO

proliferation CRISPR screen from WTC11 (ENCSR482PHH)

2026-02-28 | GSE321985 | GEO

proliferation CRISPR screen from WTC11 (ENCSR793DSE)

2026-02-28 | GSE321289 | GEO

proliferation CRISPR screen from WTC11 (ENCSR071ZGB)

2026-02-28 | GSE320734 | GEO

proliferation CRISPR screen from WTC11 (ENCSR117YGQ)

2026-02-28 | GSE320818 | GEO

proliferation CRISPR screen from WTC11 (ENCSR254SJU)

2026-02-28 | GSE321968 | GEO